METHOD FOR PREVENTION OF HEALTHCARE-ASSOCIATED INFECTIONS IN PATIENTS IN CHRONIC CRITICAL CONDITION Russian patent published in 2024 - IPC A61K35/76 A61P11/00 A61P31/04 

FIELD: medicine.

SUBSTANCE: method for preventing infections associated with the provision of medical care in patients in a chronic critical condition relates to medicine, namely to anaesthesiology-resuscitation, and can be used for prevention of healthcare-associated infections (HAI), in patients with high risk of infectious complications in chronic critical condition (CCC). Patient belongs to the HAI risk group by molecular genetic analysis of potential infectious agents and their resistance genes in bronchoalveolar lavage (BAL), or sputum, or endotracheal aspirate (ETA), as well as in intestinal contents by polymerase chain reaction on the first day of admission to hospital. Risk of HAI is determined by detecting ESKAPE microorganisms in titre of more than 10⁴ CFU/ml, genes of resistance to beta-lactam and glycopeptide antibiotics in DNA preparations obtained from the analysed human preparation, intestinal dysbiosis. Prevention of HAI is performed by inhalation introduction of a basic complex of bacteriophages containing phages, which are active against bacteria, the main pathogens of HAI of the respiratory tract, obtained from the biomaterial of the patients of the given institution, which is adapted to a specific department. And also by oral administration of a basic bacteriophage complex containing phages, which are active against bacteria of the main HAI pathogens, obtained from the biomaterial of the patients of the given institution, colonizing the intestine, adapted to a specific department. Ready form containing an adapted composition of bacteriophages, which is an active substance in the form of a mixture of sterile purified bacteriophages in a Gratia concentration of 10⁴–9.9×10⁷ PFU/cm³ in 1 ml, excipient in the form of physiological saline up to 5 ml is administered by inhalation to patients in dose of 5 ml 2-3 times a day for at least 7 days. As well as a ready-made form containing an adapted composition of bacteriophages, which is an active substance in the form of a mixture of sterile purified bacteriophages in concentration Gratia 10⁴–9.90×10⁷ PFU/cm³ in 1 ml, excipient in the form of physiological solution up to 10 ml is administered orally in dose of 10.0 ml 2 times a day for at least 7 days.

EFFECT: invention provides determining whether a patient belongs to a risk group for the occurrence of infectious complications, is universal and independent of classical labour-intensive and time-consuming microbiological methods.

1 cl, 1 tbl, 3 ex